The development of activating and inhibiting camelid VHH domains against human protein kinase C epsilon.
Eur J Pharm Sci
; 42(4): 332-9, 2011 Mar 18.
Article
in En
| MEDLINE
| ID: mdl-21220006
The 10 isozymes of the protein kinase C (PKC) family can have different roles on the same biological process, making isozyme specific analysis of function crucial. Currently, only few pharmacological compounds with moderate isozyme specific effects exist thus hampering research into individual PKC isozymes. The antigen binding regions of camelid single chain antibodies (VHHs) could provide a solution for obtaining PKC isozyme specific modulators. In the present study, we have successfully selected and characterized PKCÉ specific VHH antibodies from two immune VHH libraries using phage display. The VHHs were shown to exclusively bind to PKCÉ in ELISA and immunoprecipitation studies. Strikingly, five of the VHHs had an effect on PKCÉ kinase activity in vitro. VHHs A10, C1 and D1 increased PKCÉ kinase activity in a concentration-dependent manner (EC(50) values: 212-310nM), whereas E6 and G8 inhibited PKCÉ activity (IC(50) values: 103-233nM). None of these VHHs had an effect on the activity of the other novel PKC isozymes PKCδ and PKCθ. To our knowledge, these antibodies are the first described VHH activators and inhibitors for a protein kinase. Furthermore, the development of PKCÉ specific modulators is an important contribution to PKC research.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Protein Kinase C-epsilon
/
Single-Chain Antibodies
/
Isoenzymes
Limits:
Animals
/
Humans
Language:
En
Journal:
Eur J Pharm Sci
Journal subject:
FARMACIA
/
FARMACOLOGIA
/
QUIMICA
Year:
2011
Document type:
Article
Affiliation country:
Netherlands
Country of publication:
Netherlands